A Study to Evaluate the Biosimilarity of GLR1044 Injection and Dupilumab Injection (Dupixent®) in Healthy Adult Male Subjects

NCT07334496 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

198

Enrollment

INDUSTRY

Sponsor class

Conditions

Biosimilarity

Interventions

DRUG: GLR1044 injection
DRUG: Dupilumab Injection

Sponsor

Gan & Lee Pharmaceuticals.